PHARMACYTE BIOTECH INC (PMCB) Institutional Shareholders

PHARMACYTE BIOTECH INC (PMCB) is currently reported in institutional portfolios tracked by InsiderSet based on the latest available SEC Form 13F filings for the quarter ended June 30, 2026. The institutional investors covered on this page collectively reported approximately $586,230 in PMCB holdings during the latest filing period.

Citadel Advisors Llc is currently the largest disclosed institutional shareholder of PMCB tracked by InsiderSet, reporting ownership valued at approximately $218,203 in its June 30, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $130,270.246, representing an estimated loss of -40.30% since the filing period.

The top 10 institutional shareholders tracked on this page collectively account for approximately 91% of the total disclosed PMCB value among the investors covered in this analysis. Major shareholders include Citadel Advisors Llc, Geode Capital Management, Llc, Vanguard Capital Management Llc, and several other long-term asset managers with concentrated positions in PHARMACYTE BIOTECH INC (PMCB).

This page ranks the largest institutional PMCB shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.

Institutional Holders

28

Total Reported Value

$586,230

Largest Holder

Citadel Advisors Llc

Largest Position

$218,203

Insider Transactions (90d)

0

Latest Filing Quarter

Q2 2026

New Institutional Positions

39

Funds Exiting Positions

0

NameInvestor/ManagerPortfolio %QuantityReported BalanceCurrent Estimated ValueGain/loss Since FilingEstimated Portfolio Performance
Citadel Advisors Llc0.00%283,381$218,203$130,270-$87,933-40.30%
Geode Capital Management, Llc0.00%124,247$95,681$57,116-$38,565-40.31%
Vanguard Capital Management Llc0.00%56,778$43,719$26,101-$17,618-40.30%
Susquehanna International Group, Llp0.00%44,853$34,536$20,619-$13,917-40.30%
Renaissance Technologies LLCJim Simons0.00%37,987$29,250$17,463-$11,787-40.30%
Xtx Topco Ltd0.00%34,180$26,319$15,713-$10,606-40.30%
Northern Trust Corp0.00%32,624$25,120$14,997-$10,123-40.30%
Jane Street Group, Llc0.00%30,064$23,149$13,820-$9,329-40.30%
Schonfeld Strategic Advisors Llc0.00%26,926$20,733$12,378-$8,355-40.30%
Vanguard Fiduciary Trust Co0.00%23,452$18,058$10,781-$7,277-40.30%
Equitec Proprietary Markets, Llc0.00%22,227$17,115$10,218-$6,897-40.30%
Commonwealth Equity Services, Llc0.00%20,255$15,600$9,311-$6,289-40.31%
Hrt Financial Lp0.00%15,451$11,000$7,103-$3,897-35.43%
Tower Research Capital Llc (Trc)0.00%4,888$3,764$2,247-$1,517-40.30%
Ubs Group Ag0.00%4,142$3,189$1,904-$1,285-40.29%
Group One Trading Llc0.00%500$385$230-$155-40.30%
Osaic Holdings, Inc.0.00%303$232$139-$93-39.96%
Barclays Plc0.00%192$148$88-$60-40.36%
Sachetta, Llc0.00%14$11$6-$5-41.49%
Sbi Securities Co., Ltd.0.00%6$5$3-$2-44.84%
Bfsg, Llc0.00%5$4$2-$2-42.54%
Financial Consulate, Inc0.00%2$2$1-$1-54.03%
Newedge Advisors, Llc0.00%2$2$1-$1-54.03%
Blackrock, Inc.0.00%1$1$0-$1-54.03%
Cwm, Llc0.00%1$1$0-$1-54.03%
Johnson Financial Group, Inc.0.00%1$1$0-$1-54.03%
Mcf Advisors Llc0.00%1$1$0-$1-54.03%
Morgan Stanley0.00%1$1$0-$1-54.03%
Showing 28 of 28

Frequently asked questions about PMCB

  • Who owns the most PMCB stock?

    The largest holders of PMCB are typically major institutional investors such as asset managers and hedge funds reporting on Form 13F. The table above ranks tracked superinvestors by reported position size using the latest available filings for PHARMACYTE BIOTECH INC (PMCB).

  • Is PMCB widely held by superinvestors?

    Many widely followed stocks like PMCB appear across numerous superinvestor portfolios because of liquidity, index inclusion, and fundamentals. The holder count and table above show how broadly PMCB is represented among the institutional managers we track.

  • What do “Current Estimated Value”, “Gain/loss Since Filing”, and “Estimated Portfolio Performance” mean?

    Current Estimated Value is reported share quantity from the latest 13F times our most recent split-adjusted U.S. session close. Gain/loss Since Filing is that estimate minus the reported 13F dollar value; Estimated Portfolio Performance is that difference as a percent of the reported value. Green means the estimate is above the filing value; red means below (not purchase cost). If many filers share the same implied filing price per share, the performance % may match across rows. These are not official fund marks or live quotes.